Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial

Pengfei Jin(Jiangsu Provincial Center for Disease Control and Prevention), Jingxin Li(Shandong University), Zhuopei Li(Nanjing Medical University), Gao Chunjing(Jiangsu University), Mingdong Ding(Nantong University), Limei Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Hongmei Jiang(Shandong First Medical University), Qiao Liu(Jiangsu Provincial Center for Disease Control and Prevention), Siyue Jia(Jiangsu Provincial Center for Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Mingwei Wei(Jiangsu Provincial Center for Disease Control and Prevention), Rui-Mei Zhang(Jiangsu University), Yuansheng Hu(Sinovac Biotech), Xilin Guo(Jiangsu Provincial Center for Disease Control and Prevention), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Jianfeng Wang(Xi’an Jiaotong-Liverpool University), Wen‐Li Chen(Harbin Institute of Technology), Li Zhou(Central South University), Zhao-Lan Cao(The First People’s Hospital of Lianyungang), Xiaoyin Zhang(Southeast University), Kui Zhang(Chinese Academy of Sciences), Xin Xia(Nanjing Medical University), Yanfei Wu(Fudan University), Jia He(Xinjiang Uygur Autonomous Region Disease Prevention and Control Center), Yawen Zhu(Nanjing Medical University), Tiantian Zhang(University of Jinan), Gang Zeng(Sinovac Biotech)
Expert Review of Vaccines
November 11, 2024
Cited by 0


Related Papers